Clinical trial SOLSTICE
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients with Cytomegalovirus (CMV) Infections that are Refractory or Resistant to Treatment with Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
Cancers | |
---|---|
Organ | Multiple |
Trial status | Trial closed |
Trial type |
Interventional with experimental drug
|
Phase | Trial phase 3 |
Academic trial | Non |
Sponsor | Shire |
EudraCT Identifier | 2015-004725-13 |
ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT02931539 |
Inclusion criteria | HSCT, refractory or resistant CMV reactivation |
Last update |